Home/Pipeline/Beizray (docetaxel + albumin)

Beizray (docetaxel + albumin)

Oncology

CommercialMarketed

Key Facts

Indication

Oncology

Phase

Commercial

Status

Marketed

Company

Zydus Cadila

About Zydus Cadila

A global, fully integrated pharmaceutical company developing and manufacturing generic medicines, small molecules, biologics, and vaccines across multiple therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Infectious Disease Dermatology Neurology Immunology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active